Vaccitech

About Vaccitech

Vaccitech is a clinical stage T cell immunotherapy company developing products to treat and prevent cancer and infectious diseases. The company’s proprietary technology platform, comprising
Chimpanzee Adenovirus (prime) and MVA (boost) is exceptional at inducing, boosting and maintaining CD8+ and CD4+ T cells, as well as antibodies. The Vaccitech prime-boost platform is licensed from one of the most prestigious vaccine research institutes in the world, the Jenner Institute at the University of Oxford. Vaccitech currently has a Phase 2 clinical program for prostate cancer, a Phase 1 clinical program for chronic HBV and is poised to enter the clinic with HPV and NSCLC therapeutics. The company is also co-developing products for MERS coronavirus and Herpes Zoster with international collaborators and has outlicensed its rights to the ChAdOx COVID-19 vaccine being developed by the University of Oxford to AstraZeneca. Vaccitech is backed by leading institutions including M&G, GV, Gilead Sciences, Sequoia Capital China, Korea Investment Partners and Oxford Sciences Innovation.

Website	http://www.vaccitech.co.uk
Employees	11-50 employees View all Vaccitech employees
Industry	Biotechnology
Headquarter	Vaccitech plc, 2nd Floor Schrodinger Building, Oxford Science Park, Oxford, Oxfordshire OX4 4GE, GB
Founded	2016
Keywords	Research, Oncology, Immunotherapy, Infectious Disease, Vaccines, Viral Vectors, Hpv, Hbv, Prostate Cancer, Non-Small Cell Lung Cancer